SEARCH

SEARCH BY CITATION

References

  • Murray CJL, Lopez AK, eds.
    The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and projected to 2020. Boston, MA, USA. Harvard University Press, 1996.
  • 2
    Beaglehole R. International trends in coronary heart disease mortality, morbidity, and risk factors. Epidemiol Rev 1990; 12: 1 15.
  • 3
    Sverre JM. Secular trends in coronary heart disease mortality in Norway, 1966–1986. Am J Epidemiol 1993; 137: 301 10.
  • 4
    Sytkowski PA, D'agostino RB, Belanger A, Kannel WB. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950–1989. Am J Epidemiol 1996; 143: 338 50.
  • 5
    Hunink MGM, Goldman L, Tosteson ANA, Mittleman MA, Goldman PA, Williams LW. The recent decline in mortality from coronary heart disease, 1980–1990: the effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535 42.
  • Marmot MG. Coronary heart disease: rise and fall of a modern epidemic. In: Marmot MG, Elliott P, eds.
    Coronary Heart Disease Epidemiology. Oxford UK Oxford University Press, 1992, 3–19.
  • 7
    Marmot MG. Changing places changing risks: the study of migrants. Public Health Rev 199394; 21: 185 95.
  • 8
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane Pw for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301 7.
  • 9
    Humphries SE, Peacock RE, Talmud PJ. The genetic determinants of plasma cholesterol and response to diet. Baillière's Clin Endocrinol Metab 1995; 9: 797 823.
  • 10
    Harrap SB. Hypertension: genes versus environment. Lancet 1994; 344: 169 71.
  • 11
    Pillay TS, Langlois WJ, Olefsky JM. The genetics of non-insulin-dependent diabetes mellitus. Adv Genetics 1995; 32: 51 98.
  • 12
    Khoury MJ, Beaty TH, Liang KY. Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol 1988; 127: 674 83.
  • 13
    Hopkins PN & Williams RR. Human genetics and coronary heart disease: a public health perspective. Annu Rev Nutr 1989; 9: 303 45.
  • 14
    Barker DJP. Growth in utero and coronary heart disease. Nutr Rev 1996; 54: S1 S7.
  • 15
    Cooper RS. Ethnicity and disease prevention. Am J Hum Biol 1993; 5: 387 98.
  • 16
    Hobbs HH & Brown Ms; Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445 66.
  • 17
    Tybjærg-Hansen A. Rare and common mutations in hyperlipidemia and atherosclerosis. Scand J Clin Lab Invest 1995; 55(suppl 220); 57 76.
  • 18
    Williams RR, Hunt SC, Hopkins PN, Wu LL, Labouel JM. Tabulations and expectations regarding the genetics of human hypertension. Kidney Int 1994; 45(Suppl 44); S57 S64.
  • 19
    Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. JAMA 1994; 272: 1666 71.
  • 20
    Gerdes LU, Klausen IC, Sihm I, Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol 1992; 9: 155 67.
  • 21
    Sepehrnia B, Kamboh MI, Adams-Campbell LL, Bunker CH, Nwankwo M, Majumder PP. Genetic studies of human apolipoproteins. X. The effect of the apolipoprotein E polymorphism on quantitative levels of lipoproteins in Nigerian Blacks. Am J Hum Genet 1989; 45: 586 91.
  • 22
    Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A. Effects of the apolipoprotein(a) size polymorphism on lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991; 86: 607 14.
  • 23
    Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet 1997; 349: 397.
  • 24
    Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996; 58: 17 20.
  • 25
    Cooper R, Rotimi C, Ataman S, McGee D, Osotime in B, Kadiri S et al. The prevalence of hypertension in seven populations of west African origin. Am J Public Health 1997; 87: 160 8.
  • 26
    King H & Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993, 16: 157 77.
  • 27
    Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology-from west to the rest. Diabetes Care 1992; 15: 232 52.
  • 28
    Rose G. Population distributions of risk and disease. Nutr Metab Cardiolvasc Dis 1991; 1: 37 40.
  • 29
    Berg K, Kondo I, Drayna D, Lawn R. ‘Variabilty gene’ effect of cholesterol ester transfer protein (CETP) genes. Clin Genet 1989; 35: 437 45.
  • 30
    Hayden MR, Liu MS, Ma Y. Gene environment interaction and plasma triglyceride levels: the crucial role of lipoprotein lipase. Clin Genet 1994; 46: 15 8.
  • 31
    Fisher RM, Mailly F, Peacock RE. Interaction of the lipoprotein lipase asparagine 291->serine mutation with body mass index determines elevated triacyiglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors and healthy adults. J Lipid Res 1995; 36: 2104 12.
  • 32
    Lehtimäkti T, Moilanen T, Porkka K, Akerblom HK, Ronnemaa T, Rasanen L et al. Association between serum lipids and apolipoprotein E phenotype is influenced by diet in a population-based sample of free-living children and young adults: the Cardiovascular Risk in Young Finns Study. J Lipid Res 1995; 36: 653 61.
  • 33
    Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7 9.
  • Tonstad S, Refsum H, Ose L, Ueland PM. The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine.
    J Pediatr in press.
  • 35
    Hopkins PN, Williams RR, Hunt SC. Magnified risks from cigarette smoking for coronary prone families in Utah. Western J Med 1984; 141: 196 202.
  • 36
    Sun XM, Patel DD, Webb JC, Knight BL, Fan LM, Cai HJ. Familial hypercholesterolemia in China. Identification of mutations in the LDL-receptor gene that results in a receptor-negative phenotype. Arterioscler Thromb 1994; 14: 85 94.
  • 37
    Sing CF, Kaprio J, Perusse L, Moll PP. Genetic differences in risk of disease within and between populations. World Rev Nutr Diet 1990; 63: 220 35.
  • 38
    Austin MA. Genetics of low-density lipoprotein subclasses. Current Opinion Lipidol 1993; 4: 125 32.
  • 39
    Dreon DM, Fernstrom H, Miller B, Krauss RM. Low density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J 1994; 8: 121 6.
  • 40
    Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Circulation 1995; 92: 1779 85.
  • 41
    Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771 4.
  • 42
    Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353 7.
  • 43
    Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488 96.
  • 44
    Miettinen TA, Pedersen T, Pyörälä K, Kjekshus 3. Clinical outcome in coronary heart disease patients ≥65 years of age in the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17(suppl): 532.